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MMP-9 triggered micelle-to-ﬁbre transitions for
slow release of doxorubicin†
Daniela Kalafatovic,a Max Nobis,b Nadeem Javid,a Pim W. J. M. Frederix,a
Kurt I. Anderson,b Brian R. Saundersc and Rein V. Ulijn*a,d,e
Phenylacetyl-peptide amphiphiles were designed, which upon
cleavage by a disease-associated enzyme reconﬁgure from micellar
aggregates to ﬁbres. Upon this morphological change, a doxo-
rubicin payload could be retained in the ﬁbres formed, which
makes them valuable carriers for localised formation of nanoﬁbre
depots for slow release of hydrophobic anticancer drugs.
Peptide self-assembly is increasingly being investigated for a
plethora of applications in biomedicine including drug
release, tissue engineering, diagnostic studies and regenerative
medicine.1 These nanostructures are of interest as they may
contain bioactive peptide ligands, as well as structural com-
ponents which enable access to a variety of nanoscale mor-
phologies dictated by the amino acid sequence2 but also by
the route of assembly.3 Enzymatic catalysis presents an attrac-
tive way to control molecular self-assembly.4 In this approach,
non-assembling precursors that are “blocked” with enzyme
cleavable groups are converted to self-assembling building
blocks (including hydrogelators), enabling self-assembly on-
demand under physiological conditions. The most frequently
studied biocatalytic self-assembly systems are those based on
aromatic peptide amphiphiles. They consist of short peptide
sequences modified by aromatic groups such as phenyl,
naphthyl, fluorenyl and others.5 Diﬀerent enzymes such as
phosphatases4b,6 and proteases (including matrix metallopro-
teinases (MMPs))7 have been used to trigger molecular self-
assembly in vitro and in vivo.6c,8
Expression levels of enzymes dictate the diﬀerence between
health and disease in many cases, including cancer. MMPs are
a family of zinc dependent endopeptidases that are involved in
the digestion and remodelling of the extracellular matrix.9
Some members of this family, such as MMP-9, have been
reported to be overexpressed in breast, cervical, colon and
other types of cancers.10 This makes them valuable triggers for
responsive biomaterials and targeted self-assembly. Typically,
MMP responsive peptide-based systems act via hydrolysis and
dissociation of structures, i.e. using enzymatic cleavage to
trigger dissociation of hydrogels (containing MMP sensitive
crosslinks),11 supramolecular peptide filaments12 and polymer–
peptide hybrids.13 The first example of the use of MMP-9 to
form (rather than degrade) a peptide based supramolecular
hydrogel was presented by the Xu group.7a A morphological
change induced by MMP-7 was previously shown for an
aliphatic, palmitylated peptide amphiphile system.14 A very
recent study shows the development of a selective assay for
MMP-9 via gelation.15
Based on this knowledge we set out to develop a peptide
based enzyme-responsive system that is able to undergo a mor-
phological change from micellar aggregates to fibres in
response to cleavage by MMP-9 (Fig. 1) and use it for localised
formation of a depot for slow release of hydrophobic drugs
(e.g. doxorubicin) at the cancer site. There are three design
requirements for such a system: (i) a biocompatible fibre
forming self-assembly unit (phenylacetyl-FFAG) that also pro-
vides the hydrophobic binding region for drug candidates, (ii)
the MMP-9 cleavable sequence and (iii) a hydrophilic unit
(LDD) that modifies the amphiphilic balance of the precursor
to favour micelle formation (Fig. 1). Thus, upon MMP-9 clea-
vage, the peptide micelles reconfigure into fibres, due to a
change in the hydrophobic/hydrophilic balance of the
sequence. In turn, this aspect may be used for hydrophobic
drug entrapment into fibres, presenting a unique advantage
for the development of drug delivery systems for prolonged
release times after initial exposure.
In order to design the enzyme cleavage site, the MEROPS16
database was used, which provides cleavage patterns for pepti-
dases based on a collection of experimental data from the
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simultaneously meet the three criteria mentioned above.
MMP-9’s specificity preference for P4–P3′ subsites (based on
367 cleavages reported in the literature) is based on the
GPX1G↓LX2G sequence with G/L (P1–P1′) being the cleavable
bond, X1 (P2) being preferentially alanine or leucine, and X2
(P2′) glycine as the preferred choice.16 MMP-9 requires longer
substrates, of e.g. 7 residues (i.e. P4–P3′), in order to be able to
recognise and eﬃciently cleave the G↓L bond,17 with
GPLG↓LAG being an example.18 The length of the substrate
and the presence of large substitutions (i.e. pyrene, naphtha-
lene, etc.) at the N-terminus can lead to a shift in specificity of
MMP-9.7b To fulfil the requirement of the gelator (fibre
forming) unit in the P3 and P4 positions phenylalanine–
phenylalanine19 was used (proline and glycine preferred, but
phenylalanine known to be tolerated in P3 and P4). In P2 we
chose alanine, while in P2′ and P3′ (referred to as amino acids
flanking the scissile bond towards the C-terminus) aspartic
acid–aspartic acid was used, as it is known to be tolerated in
both positions, and will provide a negatively charged surface
of the micellar aggregates.
First the PhAc-FFAGLDD (1a) and its expected product of
enzyme cleavage PhAc-FFAG (1b) were synthesized and charac-
terized by AFM, FTIR, DLS, rheology and fluorescence.
The peptide (1a) was directly dissolved in deionized water,
the pH adjusted to 7.4 and its self-assembly behaviour investi-
gated after a cycle of alternating sonication and vortexing. For
the expected enzyme cleavage peptide fragment, i.e. 1b the
peptide was dissolved in DI water and the pH was increased
(0.5 M NaOH) to solubilise 1b, followed by a slow decrease of
pH achieved by addition of 0.5 M HCl, to a final pH of 6.5–7.
This slightly acidic pH corresponds to that of the tumour
microenvironment.20 Gelation was observed for the expected
MMP-9 cleavage product 1b (Fig. 2A).
The AFM characterisation of the peptides revealed spherical
aggregates for 1a (d = 43.6 ± 6.2 nm) while fibres were found
for 1b having a micron scale length and 20–50 nm range dia-
meter which corresponds to the size of peptide based fibres
reported in the literature.2c Alternative supramolecular organis-
ation was further supported by infrared (IR) spectroscopy data
(Fig. 2C) suggesting the presence of ordered structures for the
examined peptides due to aggregation via intramolecular
hydrogen bonding.21 Peptide 1a shows a red shift and a broad
peak at 1643 cm−1 compared to 1650–1655 cm−1 absorption
values, typical for free peptides in solution. The
1570–1580 cm−1 absorption band is attributed to the aspartic
acid side chain carboxylate group present in 1a.21 Extended
structures are observed for 1b (transparent gel) characterised
by a pronounced narrowing of the peak typical for short
peptide β-sheets at 1630 cm−1, while the 1595 cm−1 character-
istic of the C-terminus carboxylate group has a low inten-
sity.21,22 Rheology measurements of the 1b hydrogel show the
elastic modulus (G′) of 360 Pa, an order of magnitude higher
than its viscous component (G″ = 32 Pa) which is characteristic
of entangled networks (Fig. 2B). Furthermore, DLS experi-
ments (Fig. S3 and S4, ESI†) were performed for peptide solu-
tion samples 1a and 1b at various concentrations ranging from
0.625 mM to 5 mM. The diﬀusion coeﬃcients (D) of samples
1a (micellar aggregates) and 1b (fibres) at 0.625 mM are 1.5 ×
10−12 m2 s−1 and 6.8 × 10−13 m2 s−1 corresponding to RH
values of 165 nm and 358 nm, respectively. The higher values
of RH compared to AFM (dry samples) indicate that in the
solution state the aggregates are bigger than the collapsed,
dried ones.
In order to further investigate the self-assembly behaviour
of peptide amphiphiles the critical aggregation concentration
(CAC) in water was determined using the fluorescence intensity
of the 8-anilino-1-naphthalenesulphonic acid (ANS probe) as a
function of the peptide concentration (Fig. S5, ESI†). The
determined CAC values were 1.32 mM for PhAc-FFAGLDD and
Fig. 1 (A) Schematic representation of micelle to ﬁbre transition
induced by MMP-9 cleavage showing disassembly of micelles and the
re-assembly into ﬁbres after the removal of the hydrophilic group
enabling prolonged drug release. (B) Chemical structure of the biocata-
lytic gelation system and its components.
Fig. 2 (A) AFM showing the micellar aggregates (solution) for 1a and
ﬁbres (hydrogels at 20 mM) for 1b. (B) Rheology data for 1b gel showing
the plot of G’ (elastic modulus) and G’’ (viscous modulus) against fre-
quency. (C) FTIR absorption spectrum in the amide I region (in D2O at
pH 7): 1a (solution) and 1b (gel). (D) Critical aggregation concentration
(CAC) of (1.32 mM (1a) and 2.88 mM (1b)).
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2.88 mM for PhAc-FFAG. Furthermore, the critical micelle con-
centration (CMC) for 1a was determined using pyrene as the
fluorescent probe. The ratio of the fluorescence intensity of
the first (λem = 372 nm) and the third peak (λem = 384 nm) was
plotted as the function of the peptide concentration. The value
calculated to be 1.25 mM (Fig. S6, ESI†) is in the same range
of the CAC values for 1a.
After the designed peptides 1a and 1b were shown to be
successful for controlling the morphology of the supramolecu-
lar aggregates based on the peptide length, i.e. hydrophobicity,
the enzyme triggered micelle to fibre transition for peptide
amphiphile 1a was explored. Peptide amphiphile 1a was
treated with 50 ng mL−1 MMP-9 for 96 h and the morphologi-
cal change was monitored by AFM, where fibre formation was
observed (Fig. 3B). This enzyme concentration was chosen
based on MMP-9 quantification of in vitro human cancer cell
lines. Peptide 1a showed complete conversion after 96 h to the
PhAc-FFAGL (1c) fragment (Fig. S7, ESI†) indicating the shift
of the MMP-9 specificity for this heptapeptide to GL↓D instead
of the expected G↓L in accordance with reported observations
that cleavage sites of heptapeptides catalysed by MMP-9 diﬀer
from those of longer peptide sequences.7b According to
MEROPS leucine and aspartic acid are tolerated in P1 and P1′
positions, respectively, but they do not seem to be preferen-
tially recognised and reported as a cleavage site for MMP-9.
Following this it was investigated whether the micelles were
capable of performing as mobile vehicles for encapsulation to
immobilised fibre networks for the release of hydrophobic
drugs. For this purpose, the release of an anticancer drug,
doxorubicin, was studied. Doxorubicin was loaded into the
micelles and its release by passive diﬀusion was monitored
over time by fluorescence microscopy. The fluorescence inten-
sity of doxorubicin at 596 nm which corresponds to the
maximum intensity (λex = 480 nm) was monitored over 96 h
when incorporated into the 1a peptide system. A control experi-
ment with free doxorubicin shows a decrease in fluorescence
intensity over time, probably due to aggregation. Due to its
poor solubility in water, fluorescence quantification of doxo-
rubicin is not reproducible, however, it becomes more stable
when incorporated into peptides. The interaction of doxorubi-
cin with the hydrophobic environment of 1c results in higher
values of fluorescence intensity compared to free doxorubicin
in water (doxorubicin emission in solvents of diﬀerent
polarities is shown in Fig. S8, ESI†). For 1a doxorubicin fluo-
rescence intensity drops only slightly over 48 h suggesting that
the payload stays incorporated into micelles over that time
period showing only low release, followed by a significant
decrease after 72 h. When treated with MMP-9 there is a
release from micelles (a significant drop in fluorescence inten-
sity upon exposure to water) followed by entrapment into
fibres (resulting in an increase in fluorescence intensity). A
similar discontinuous behaviour upon phosphatase triggered
gelation was recently reported for a related system.23 Even if
the overall release after 48 h is similar for the MMP-9 treated
and untreated 1a the advantage of the enzymatic approach is
that a localised eﬀect is obtained with fibres expected to be
significantly less mobile than the micelles.
After fibre formation, the increase of fluorescence intensity
suggests that the doxorubicin re-enters a hydrophobic environ-
ment by becoming entrapped in the fibres, confirming the
possibility of the system to temporarily retain the payload.
TEM images were obtained on enzyme treated doxorubicin
loaded peptides that confirm fibre formation and show that
the presence of doxorubicin did not disrupt fibre formation
(Fig. 3C).
In conclusion, an MMP-9 responsive peptide amphiphile is
shown here that self-assembles into spherical aggregates.
Enzyme triggered micelle to fibre transition shows that it is a
substrate of MMP-9 and is capable of encapsulation and con-
trolled release of doxorubicin. These observations suggest the
use as a mobile carrier for the anticancer drug that in turn is
expected to be selectively delivered to tumour tissues, where it
assembles to form a localised fibre-based depot by exploiting
local MMP-9 overexpression. Furthermore, the assembled fibres
provide a scaﬀold for localised drug delivery due to the partial
entrapment of the drug and the intrinsic biodegradable nature
of peptide carriers themselves. These systems are now studied
in animal models. It should be noted that when used in vivo
the system may also respond to other MMPs and specifically to
MMP-2 due to some overlapping in specificity profiles.24
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